TrialJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2014

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

Elizabeth J Samelson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.